Posaconazole to prevent fungal infection in stem cell transplant patients with gut GVHD
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant for a blood disease.
- You are being prescribed posaconazole tablets to prevent fungal infections for the first time or are already taking them.
- You have or have developed acute gut GVHD that needs treatment with steroids, with or without other immune-suppressing drugs.
- You are willing to take part in the study and sign a consent form.
- You are not pregnant or breastfeeding.
- You do not have a known serious allergy to azole antifungal drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
This study looks at how posaconazole (an antifungal medicine) moves through the body in people who recently had an allogeneic stem cell transplant and have mouth sores (mucositis). It may help clinicians choose the safest and most effective dosing for preventing serious fungal infections.
This trial tests whether posaconazole, given through a vein or by mouth, can treat invasive fungal infections in children under 2 years old. It may help improve outcomes for infants with hard-to-treat fungal disease.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
Hear when a new Invasive Fungal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.